PURPOSE: To assess the feasibility of a one-step surgical concept, employing adipose stem cells (ASCs) and a novel degradable radiolucent cage filler (poly-L-lactide-co-caprolactone; PLCL), within polyetheretherketone cages in a stand-alone caprine spinal fusion model. METHODS: A double-level fusion study was performed in 36 goats. Four cage filler groups were defined: (i) acellular PLCL, (ii) PLCL + SVF (freshly harvested stromal vascular fraction highly enriched in ASCs); (iii) PLCL + ASCs (cultured to homogeneity); and (iv) autologous iliac crest bone graft (ABG). Fusion was assessed after 3 and 6 months by radiography, micro-CT, biomechanics, and biochemical analysis of tissue formed inside the cage after 6 months. RESULTS: No adverse effects were observed in all groups. After 3 months, similar and low fusion rates were found. Segmental stability did not differ between groups in all tested directions. Micro-CT imaging revealed significantly higher amounts of mineralized tissue in the ABG group compared to all others. After 6 months, interbody fusion rates were: PLCL 53%, SVF 30%, ASC 43% and ABG 63%. A trend towards higher mineralized tissue content was found for the ABG group. Biochemical and biomechanical analyses revealed equal maturity of collagen cross-links and similar segmental stability between all groups. CONCLUSIONS: This study demonstrates the technical feasibility and safety of the one-step surgical procedure for spinal fusion for the first time. The radiolucent PLCL scaffold allowed in vivo monitoring of bone formation using plain radiography. Addition of stem cells to the PLCL scaffolds did not result in adverse effects, but did not enhance the rate and number of interbody fusions under the current conditions. A trend towards superior results with ABG was found. Further research is warranted to optimize the spinal fusion model for proper evaluation of both PLCL and stem cell therapy.
PURPOSE: To assess the feasibility of a one-step surgical concept, employing adipose stem cells (ASCs) and a novel degradable radiolucent cage filler (poly-L-lactide-co-caprolactone; PLCL), within polyetheretherketone cages in a stand-alone caprine spinal fusion model. METHODS: A double-level fusion study was performed in 36 goats. Four cage filler groups were defined: (i) acellular PLCL, (ii) PLCL + SVF (freshly harvested stromal vascular fraction highly enriched in ASCs); (iii) PLCL + ASCs (cultured to homogeneity); and (iv) autologous iliac crest bone graft (ABG). Fusion was assessed after 3 and 6 months by radiography, micro-CT, biomechanics, and biochemical analysis of tissue formed inside the cage after 6 months. RESULTS: No adverse effects were observed in all groups. After 3 months, similar and low fusion rates were found. Segmental stability did not differ between groups in all tested directions. Micro-CT imaging revealed significantly higher amounts of mineralized tissue in the ABG group compared to all others. After 6 months, interbody fusion rates were: PLCL 53%, SVF 30%, ASC 43% and ABG 63%. A trend towards higher mineralized tissue content was found for the ABG group. Biochemical and biomechanical analyses revealed equal maturity of collagen cross-links and similar segmental stability between all groups. CONCLUSIONS: This study demonstrates the technical feasibility and safety of the one-step surgical procedure for spinal fusion for the first time. The radiolucent PLCL scaffold allowed in vivo monitoring of bone formation using plain radiography. Addition of stem cells to the PLCL scaffolds did not result in adverse effects, but did not enhance the rate and number of interbody fusions under the current conditions. A trend towards superior results with ABG was found. Further research is warranted to optimize the spinal fusion model for proper evaluation of both PLCL and stem cell therapy.
Authors: Iris Busscher; Jaap H van Dieën; Idsart Kingma; Albert J van der Veen; Gijsbertus J Verkerke; Albert G Veldhuizen Journal: Spine (Phila Pa 1976) Date: 2009-12-15 Impact factor: 3.468
Authors: Patricia A Zuk; Min Zhu; Peter Ashjian; Daniel A De Ugarte; Jerry I Huang; Hiroshi Mizuno; Zeni C Alfonso; John K Fraser; Prosper Benhaim; Marc H Hedrick Journal: Mol Biol Cell Date: 2002-12 Impact factor: 4.138
Authors: Matthijs R Krijnen; Margriet G Mullender; Theo H Smit; Vincent Everts; Paul I J M Wuisman Journal: Spine (Phila Pa 1976) Date: 2006-06-15 Impact factor: 3.468
Authors: Jed Vanichkachorn; Timothy Peppers; Dennis Bullard; Scott K Stanley; Raymond J Linovitz; James T Ryaby Journal: Eur Spine J Date: 2016-02-05 Impact factor: 3.134
Authors: Henk-Jan Prins; Engelbert A J M Schulten; Christiaan M Ten Bruggenkate; Jenneke Klein-Nulend; Marco N Helder Journal: Stem Cells Transl Med Date: 2016-07-07 Impact factor: 6.940
Authors: Andrea Friedmann; Andre Baertel; Christine Schmitt; Christopher Ludtka; Javorina Milosevic; Hans-Joerg Meisel; Felix Goehre; Stefan Schwan Journal: Int J Mol Sci Date: 2021-04-19 Impact factor: 5.923
Authors: Milan Krticka; Ladislav Planka; Lucy Vojtova; Vladimir Nekuda; Premysl Stastny; Radek Sedlacek; Adam Brinek; Michaela Kavkova; Eduard Gopfert; Vera Hedvicakova; Michala Rampichova; Leos Kren; Kvetoslava Liskova; Daniel Ira; Jana Dorazilová; Tomas Suchy; Tomas Zikmund; Jozef Kaiser; David Stary; Martin Faldyna; Martin Trunec Journal: Biomedicines Date: 2021-06-25